Physician profile
Mark A Kasari
NPI 1942209853
$2,078.13
in general payments reported to CMS, 2019-2025
20 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $102 · 2021: $161 · 2022: $253 · 2023: $276 · 2024: $525 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143 · Education: $38.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.34 |
| Education | $38.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $270.28 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $251.08 | 2019-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $248.03 | 2022-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $243.28 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Enterprises LLC | $171.29 | 2019 | |
| Travere Therapeutics, INC. | $135.74 | 2024-2025 | |
| Glaxosmithkline, LLC. | $106.40 | 2022-2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $78.46 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $74.99 | 2020 | |
| Vifor Pharma, INC. | $70.69 | 2019-2024 | Veltassa |
| Opko Pharmaceuticals, LLC | $66.71 | 2019-2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $63.89 | 2022-2024 | Lupkynis |
| Horizon Therapeutics Plc | $63.31 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $58.77 | 2021-2025 | Velphoro |
| Ardelyx, INC. | $49.70 | 2024-2025 | Ibsrela |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $48.76 | 2024-2025 | In.Pact Av, Ellipsys Vascular Access System |
| Novo Nordisk INC | $28.78 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.63 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $16.36 | 2023 | Ultomiris |
| Calliditas Therapeutics US INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kasari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.